Latest news with #Terumo
Business Standard
23-06-2025
- Business
- Business Standard
Terumo India is Great Place to Work®- Certified for the Fourth Time
VMPL New Delhi [India], June 23: Terumo India, the Indian arm of global medical technology leader Terumo Corporation (TSE: 4543), has been recognized as a Great Place to Work® for the fourth time, strengthening its position as an employer of choice in the healthcare industry. The certification also reaffirms the company's ongoing commitment to cultivating a culture of trust, respect, and associate well-being, aligned with Terumo's EVP statement of "Advancing Healthcare with Heart." The Great Place to Work® Certification is a globally respected benchmark for workplace culture. Terumo India's recognition followed a rigorous evaluation process, including anonymous associate feedback, a culture audit of people practices, and in-depth interactions across all levels of the organization. Achieving this certification for the fourth time in a row demonstrates Terumo India's success in consistently creating a work environment where associates thrive and feel valued. "Securing the Great Place to Work® Certification for the fourth time is a proud moment for all of us at Terumo India. This achievement reflects the collaborative spirit we've nurtured--where every associate feels respected, valued, and empowered. Our people are at the core of our success, and this recognition validates the inclusive and growth-driven culture we've worked tirelessly to build. I'm incredibly proud of our team's dedication and remain committed to ensuring an environment where everyone can thrive and contribute meaningfully to our mission of Contributing to Society through Healthcare," said Shishir Agarwal, President and Managing Director, Terumo India. Commenting on the achievement Ritu Anand, Vice President - Human Resources and Corporate Communications, Terumo India said "This recognition reflects our continued focus on listening, supporting, and growing together as an organization. At Terumo India, we are deeply guided by our 'Powered by People' philosophy, and we understand that the most successful workplaces are those that offer opportunities for both personal and professional growth. Being certified for the fourth time motivates us to continue fostering a culture where everyone feels a strong sense of belonging and purpose" This vision of creating a happier, healthier, and inspired workforce continues to guide Terumo India's HR strategy and people-centric approach. As part of its commitment to associate well-being, the company offers a wide range of initiatives from flexible work arrangements and wellness programs to continuous learning and leadership development opportunities. Programs like #TerumoCares provide holistic support to associates, helping them balance both personal and professional responsibilities. About Terumo India Private Limited Terumo India is a rapidly growing medical devices company dedicated to advancing access to high-quality cardiac, vascular, and other medical devices for patients and healthcare practitioners in India. As part of Terumo Corporation, a global leader in medical technology headquartered in Tokyo, Japan, Terumo India upholds a mission rooted in 100 years of history: 'Contributing to Society through Healthcare.' Founded in 2013 and headquartered in Gurgaon, NCR Delhi, Terumo India has touched over 100,000 lives. The company is three times Great Place to Work® certified and was also recognized as one of India's Top 15 Workplaces™ in Pharmaceuticals, Healthcare, and Biotech in 2022. Terumo India also runs several acclaimed training and development programs, collaborating closely with customers and academic partners to address the skilling needs of India's healthcare system. For more information, visit About Terumo Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large. For more information, visit (ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same)
Nikkei Asia
23-05-2025
- Business
- Nikkei Asia
Japanese medical device makers stand up to Trump tariff pressure
TOKYO -- Japanese medical device manufacturers are showing resilience to U.S. tariff threats thanks to their specialized manufacturing expertise, focus on niche markets and pricing power. Leading manufacturers such as Terumo and Olympus, both based in Tokyo, are expected to pass on at least some of the tariff costs to U.S. customers.
Yahoo
16-05-2025
- Business
- Yahoo
Terumo Corp (TRUMF) Full Year 2025 Earnings Call Highlights: Record Sales and Strategic Growth ...
Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Terumo Corp (TRUMF) achieved record high sales revenues surpassing JPY1 trillion for the first time, with a 12% growth over the previous year. Operating profit reached a record high for the fourth consecutive year, despite a one-time expense, due to strong revenue growth. Free cash flow increased significantly, exceeding JPY100 billion for the first time, driven by expanded operating cash flow. The cardiovascular company segment showed strong global sales revenue growth, particularly in the US, with an 8% increase on a local currency basis. The company expects a 32% increase in operating profit for fiscal 2025, driven by business expansion and the absence of previous one-time expenses. General and administrative expenses increased due to additional provisions for bonuses and one-time litigation expenses. The company faced negative gross margin effects due to the loss and writedown of products in preparation for new product expansion. Price declines in China due to value-based purchasing impacted revenue, although partially offset by price increases elsewhere. The impact of US reciprocal tariffs remains uncertain, with a potential maximum impact of approximately JPY17 billion. Challenges in the external environment, such as inflation and currency fluctuations, have negatively affected certain business segments. Warning! GuruFocus has detected 2 Warning Signs with TRUMF. Q: Can you elaborate on the factors driving the record high sales revenue and operating profit for fiscal year 2024? A: Jin Hagimoto, Chief Financial Officer, explained that sales revenues surpassed JPY1 trillion for the first time, with a 12% growth over the previous year. This was driven by global demand, particularly in the US, and a weaker JPY. Operating profit also reached a record high due to this growth, despite a one-time expense of 24.2 billion yen. Net income and free cash flow also hit record highs. Q: What are the expectations for fiscal year 2025 in terms of revenue and operating profit growth? A: CFO Jin Hagimoto stated that for fiscal year 2025, Terumo expects a 7% revenue growth on a local currency basis and a 32% increase in operating profit. This growth is anticipated due to business expansion and the absence of one-time expenses from the previous year. Q: How did regional performance contribute to the company's overall growth? A: CFO Jin Hagimoto highlighted that all regions showed steady progress, with the Americas and Europe posting double-digit growth. In China, the TIS segment rebounded from price declines due to value-based purchasing with increased volumes. Q: Can you discuss the impact of the US reciprocal tariffs on Terumo's financial outlook? A: CFO Jin Hagimoto mentioned that the maximum estimated impact of the US reciprocal tariffs for the current fiscal year is approximately JPY17 billion. This estimate assumes most US sales, other than those produced in the Americas, are imported from Japan. The economic impact is expected from the second quarter onwards, but it has not been factored into the fiscal 2025 guidance. Q: What strategic measures are being taken under the GS 26 growth strategy? A: CFO Jin Hagimoto outlined that the GS 26 strategy focuses on expanding therapeutic businesses, promoting radial procedures, and enhancing preoperative solutions with smart pumps. Additionally, Terumo is accelerating global expansion in blood and cell technology and expanding its software and service businesses for competitive advantage. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Recorder
14-05-2025
- Business
- Business Recorder
Japan's Nikkei reverses gains on sell-off to book profits
TOKYO: Japan's Nikkei share average reversed course to trade lower on Wednesday as investors sold stocks to book profits, while the broader Topix is set to snap its longest winning streak in nearly 16 years. The Nikkei fell 0.81% at 37,874.59 by the midday break. The broader Topix fell 1.21% to 2,738.59, on course to snap a 13-day winning streak, its longest since August 2009. The Nikkei hit a three-month high on Tuesday, buoyed by hopes for more deals between major economies after the US and China agreed to temporarily slash harsh reciprocal tariffs. 'The market had set the 38,000 as a target after the Nikkei tanked last month, following the announcement of (US President Donald) Trump's tariffs,' said Hiroyuki Ueno, chief strategist at Sumitomo Mitsui Trust Asset Management. Japan's Nikkei rises on US-China trade deal hopes 'The index hit that target earlier than expected, and that prompted investors to sell stocks to book profits today.' Uniqlo-brand owner Fast Retailing fell 1.19% to drag down the Nikkei the most. Healthcare equipment maker Terumo fell 3.3%. Yaskawa Electric fell 4.44% after the robot maker was excluded from MSCI's standard index in its regular reshuffle. Heavy machinery maker IHI rose 2.03% as it was included in the index. Of more than 1,600 stocks trading on the Tokyo Stock Exchange's prime market, 15% rose and 82% fell, with 1% trading flat.
Yomiuri Shimbun
07-05-2025
- Business
- Yomiuri Shimbun
Japan's Nikkei Heavy as US Tariff Woes Counter China Optimism
Yomiuri Shimbun file photo The Tokyo Stock Exchange TOKYO, May 7 (Reuters) – Japan's Nikkei share average ticked lower on Wednesday, threatening to end a seven-session winning streak, as pharmaceutical shares led losses after U.S. President Donald Trump said he would reveal tariffs on drugs over the next two weeks. Automaker stocks slumped as Japanese investors returned from a four-day weekend to an overall stronger yen, cutting the value of overseas revenues. Sony Group, which runs a movie studio, sank following Trump's announcement of a 100% levy on foreign-made films. Tariff worries overshadowed any improvement in market sentiment kindled by news that U.S. Treasury Secretary Scott Bessent and chief trade negotiator Jamieson Greer will meet China's economic tsar, He Lifeng, in Switzerland this weekend for talks. Investors were also reluctant to push the Nikkei above Friday's five-week peak before the conclusion of the Federal Reserve's two-day policy meeting later in the day. With so many issues regarding tariffs still unresolved, investors are not in a position to chase the market higher, said Nomura strategist Fumika Shimizu. 'The seven-day rally may be acting as a weight on the market.' The Nikkei ended the morning session down 0.05% after fluctuating in a very narrow range on either side of Friday's closing level. The biggest drags on the index included Sony and drugmaker Terumo, along with heavily weighted Uniqlo operator Fast Retailing. Sony lost 3.4%, Terumo declined 2.3% and Fast Retailing shed 1.5%. Overall, though, the Nikkei's performance was fairly balanced, with 120 of its 225 components rising, 101 falling and four flat. The broader Topix, by contrast, rose 0.4%. The Nikkei's biggest decliner in percentage terms was Sumitomo Pharma, which slumped 6.7%. Peers Otsuka Holdings and Eisai rounded out the bottom three, dropping 4.9% and 4.4% respectively. Mitsubishi Motors was the worst-faring automaker, sliding 2.7%. Toyota lost 2.1% ahead of its earnings release on Thursday. Trading houses were a bright spot after Berkshire Hathaway affirmed its commitment to investments in those businesses even as Warren Buffett stepped aside as CEO. Marubeni jumped 5.8% and Mitsubishi Corp advanced 3.4%.
